Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:04 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 2,002 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Discrete Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Closed Eye Neutrophils in Dry Eye Disease

NCT03332342
View directory record Official record
Conditions
Dry Eye, Ocular Inflammation
Interventions
Eye wash
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Nov 2, 2026, 10:04 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 2, 2026, 10:04 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Causal Role of Brain Networks in Episodic Memory

NCT05374551
View directory record Official record
Conditions
Episodic Memory, Healthy
Interventions
Transcranial magnetic stimulation
Other
Lead sponsor
Boston College
Other
Eligibility
18 Years to 35 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Measuring Active Microglia in Progressive Multiple Sclerosis

NCT02207075
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
[C11]PK-1195 PET scan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Nov 2, 2026, 10:04 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639
View directory record Official record
Conditions
Obesity
Interventions
NO-13065, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Nov 2, 2026, 10:04 PM EST
Completed No phase listed Observational Results available

Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment

NCT02637622
View directory record Official record
Conditions
Type II Diabetes
Interventions
Best-Worst Scaling (Case 2), Discrete Choice Experiment
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Nov 2, 2026, 10:04 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Prosthetic Arms for Amputee: A Better Fit and More Functionality

NCT05990062
View directory record Official record
Conditions
Amputation, Surgical
Interventions
K-Socket-Harness
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Completed Phase 1 Interventional

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

NCT05154994
View directory record Official record
Conditions
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Belinostat, Durvalumab
Drug · Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Short Dental Implants (5 mm) Versus Long Dental Implants (10 mm)

NCT04144322
View directory record Official record
Conditions
Bone Loss, Alveolar
Interventions
Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition, Zimmer T3 with Discrete Crystalline Deposition Ex Hex Parallel Walled implants
Device
Lead sponsor
University of Michigan
Other
Eligibility
20 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 2, 2026, 10:04 PM EST
Completed Not applicable Interventional

Kind Minds Program for Youth With Anxiety and Depression

NCT05353751
View directory record Official record
Conditions
Child Anxiety, Depression
Interventions
Kind Minds Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Imperial, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

The Cardiovascular Impact of Hot Flushes

NCT05251324
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
Hot Flush Induction
Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503
View directory record Official record
Conditions
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Interventions
LP-284
Drug
Lead sponsor
Lantern Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Terminated Not applicable Interventional

Storybook Reading in Individuals With Down Syndrome

NCT03764761
View directory record Official record
Conditions
Down Syndrome, Augmentative and Alternative Communication
Interventions
AAC Technology - Standard of Care, AAC Technology - non-optimal integrated arrangement
Device
Lead sponsor
Penn State University
Other
Eligibility
7 Years to 35 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Nov 2, 2026, 10:04 PM EST
Completed Phase 3 Interventional Results available

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

NCT02448680
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation FVIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Nov 2, 2026, 10:04 PM EST
Active, not recruiting No phase listed Observational

Long Term Follow-Up for Safety of AVR-RD-02

NCT06488261
View directory record Official record
Conditions
Gaucher Disease
Interventions
AVR-RD-02
Biological
Lead sponsor
John Bernat
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 2, 2026, 10:04 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Pulse Education and Children

NCT07648446
View directory record Official record
Conditions
Dysbiosis, Cardiometabolic Health Indicators, Education on Feeding and Health Status, Gut Motility
Interventions
Education Only, Education + Pulse Provision, Cooking Class
Other
Lead sponsor
Florida State University
Other
Eligibility
6 Years to 13 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Terminated Phase 1 Interventional Results available

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

NCT06048705
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3901961, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Nov 2, 2026, 10:04 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

NCT04128787
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG881 Formulation 1, AG881 Formulation 2, Omeprazole
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Nov 2, 2026, 10:04 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 2, 2026, 10:04 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Nov 2, 2026, 10:04 PM EST
Completed Not applicable Interventional

Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home

NCT02145793
View directory record Official record
Conditions
ADHD
Interventions
ADHD Group Curriculum
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Nov 2, 2026, 10:04 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Nov 2, 2026, 10:04 PM EST
Completed Not applicable Interventional

Mobile App to Promote Family Caregiver Engagement in the Intensive Care Unit

NCT05157919
View directory record Official record
Conditions
Family, Critical Care, Mobile Applications
Interventions
ICU-Care
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Nov 2, 2026, 10:04 PM EST